Try our mobile app

Published: 2022-03-25 07:35:27 ET
<<<  go to SY company page
EX-99.1 2 tm2210447d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

So-Young Reports Unaudited Fourth Quarter and Fiscal Year 2021 Financial Results

 

BEIJING, China, Mar. 25, 2022 — So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021.

 

Fourth Quarter 2021 Financial Highlights

 

·Total revenues were RMB449.5 million (US$70.5 million1), an increase of 5.9% from RMB424.6 million in the same period of 2020, in line with our previous guidance.

 

·Net loss attributable to So-Young International Inc. was RMB27.7 million (US$4.4 million), compared with net income attributable to So-Young International Inc. of RMB38.6 million in the fourth quarter of 2020.

 

·Non-GAAP net income attributable to So-Young International Inc.2 was RMB62.9 million (US$9.9 million), compared with non-GAAP net income attributable to So-Young International Inc. of RMB63.1 million in the fourth quarter of 2020.

 

Fourth Quarter 2021 Operational Highlights

 

·Average mobile MAUs were 7.4 million, compared with 8.9 million in the fourth quarter of 2020.

 

·Number of paying medical service providers on So-Young’s platform were 5,327, an increase of 12.2% from 4,746 in the fourth quarter of 2020.

 

·Number of medical service providers subscribing to information services on So-Young’s platform were 2,085, compared with 2,239 in the fourth quarter of 2020.

 

·Total number of users purchasing reservation services were 159.9 thousand and the aggregate value of medical aesthetic treatment transactions facilitated by So-Young’s platform was RMB532.7 million.

 

Fiscal Year 2021 Financial Highlights

 

·Total revenues were RMB1,692.5 million (US$265.6 million) in the full year 2021, an increase of 30.7% from RMB1,295.0 million in the prior year.

 

 

 

1This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB6.3726 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on December 30, 2021.

 

2Non-GAAP net income attributable to So-Young International Inc. is defined as net income attributable to So- Young International Inc. excluding share-based compensation expenses and impairment of goodwill and intangible assets attributable to So-Young International Inc. See “Reconciliation of GAAP and Non-GAAP Results” at the end of this press release.

 

1

 

 

·Net loss attributable to So-Young International Inc. was RMB8.4 million (US$1.3 million) in the full year 2021, compared with a net income attributable to So-Young International Inc. of RMB5.8 million in the prior year.

 

·Non-GAAP net income attributable to So-Young International Inc. was RMB139.5 million (US$21.9 million) in the full year 2021, an increase of 42.4% from RMB98.0 million in the prior year.

 

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, “We achieved 30.7% revenue growth in 2021 with total revenues at RMB1.7 billion despite the weaker-than-normal consumer sentiment as a result of the COVID-19 pandemic. We continuously strengthened operating management ability and branding digital support for medical service providers on our platform to improve their acquisition efficiency and customer experience. As a result, the number of paying medical service providers on our platform were 6,634 in 2021, up 19.1% from 5,570 year-over-year. The average mobile MAUs reached 8.5 million in 2021, up 18.7% year-over-year. ”

 

Mr. Jin continued, “In 2021, we were working to reinforce the trust with consumers, meeting medical and aesthetic consumer demand from the different levels to make efficient decisions. On the business side, we solidified our competitive advantage and completed the acquisition of Wuhan Miracle to create a competitive moat on non-surgical side. Stepping into 2022, we are committed to local aesthetic services to reaffirm our leadership position and building aesthetic supply chain ecosystem to ensure the management and control of product authenticity and supervision for customers.”

 

Mr. Min Yu, “We’re pleased to conclude 2021 with a solid revenue growth, which was very encouraging. Looking ahead, while exploring new business, we will maintain a healthy and sustainable revenue growth and earning in the long term as we continuously improve our operating efficiency and effectively control cost.”

 

Fourth Quarter 2021 Financial Results

 

Revenues

 

Total revenues were RMB449.5 million (US$70.5 million), an increase of 5.9% from RMB424.6 million in the same period of 2020. The increase was primarily due to the consolidated revenues of RMB63.8 million (US$10.0 million) in the fourth quarter of 2021 from Wuhan Miracle Laser Systems, Inc. (“Wuhan Miracle”), which was acquired on July 23, 2021.

 

·Information services and other revenues were RMB344.3 million (US$54.0 million), an increase of 2.5% from RMB335.9 million in the same period of 2020. The increase was primarily due to an increase in average revenue per paying medical service provider.

 

·Reservation services revenues were RMB41.4 million (US$6.5 million), a decrease of 53.4% from RMB88.7 million in the same period of 2020. The decrease was primarily due to the weaker-than-normal consumer sentiment and containment measures as a result of the resurgence of COVID-19, which had a negative impact on our operations in several cities across the country.

 

·Sales of equipment and maintenance services revenues were RMB63.8 million (US$10.0 million), from Wuhan Miracle, our newly acquired subsidiary.

 

Cost of Revenues

 

Cost of revenues were RMB127.1 million (US$19.9 million), an increase of 99.8% from RMB63.6 million in the fourth quarter of 2020. The increase was primarily due to the consolidation of the costs of Wuhan Miracle. Cost of revenues included share-based compensation expenses of RMB5.8 million (US$0.9 million) during the fourth quarter of 2021, compared with RMB5.0 million in the corresponding period of 2020.

 

Operating Expenses

 

Total operating expenses were RMB371.9 million (US$58.4 million), an increase of 12.3% from RMB331.2 million in the fourth quarter of 2020.

 

·Sales and marketing expenses were RMB152.7 million (US$24.0 million), a decrease of 27.4% from RMB210.4 million in the fourth quarter of 2020. The decrease was primarily due to a decrease in expenses associated with branding and marketing activities. Sales and marketing expenses for the fourth quarter of 2021 included share-based compensation expenses of RMB3.7 million (US$0.6 million), compared with RMB2.2 million in the corresponding period of 2020.

 

2

 

 

·General and administrative expenses were RMB85.9 million (US$13.5 million), an increase of 72.1% from RMB49.9 million in the fourth quarter of 2020. The increase was primarily due to the consolidation of Wuhan Miracle. General and administrative expenses for the fourth quarter of 2021 included share-based compensation expenses of RMB32.3 million (US$5.1 million), compared with RMB11.3 million in the corresponding period of 2020.

 

·Research and development expenses were RMB67.5 million (US$10.6 million), a decrease of 4.8% from RMB70.9 million in the fourth quarter of 2020. The decrease was primarily due to the decrease of payroll costs. Research and development expenses for the fourth quarter of 2021 included share-based compensation expenses of RMB7.1 million (US$1.1 million), compared with RMB5.9 million in the corresponding period of 2020.

 

·Impairment of goodwill and intangible assets was RMB65.9 million (US$10.3 million), representing the amount by which the carrying amount of certain asset exceeds their fair value in relation to the acquiring subsidiary, based on an annual goodwill and intangible assets impairment assessment. The impairment of goodwill was RMB48.5 million (US$7.6 million) and the impairment of intangible assets was RMB17.4 million (US$2.7 million).

  

Income Tax Expenses

 

Income tax expenses were RMB10.1 million (US$1.6 million), compared with RMB13.0 million in the same period of 2020.

 

Net income/(loss) attributable to So-Young International Inc.

 

Net loss attributable to So-Young International Inc. was RMB27.7 million (US$4.4 million), compared with a net income attributable to So-Young International Inc. of RMB38.6 million in the fourth quarter of 2020.

 

Non-GAAP net income attributable to So-Young International Inc.

 

Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses and impairment of goodwill and intangible assets attributable to So-Young International Inc., was RMB62.9 million (US$9.9 million), compared with RMB63.1 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2020.

 

Basic and Diluted Earnings/(Loss) per ADS

 

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.26 (US$0.04) and RMB0.26 (US$0.04), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.36 and RMB0.35, respectively, in the same period of 2020.

 

Fiscal Year 2021 Financial Results

 

Revenues

 

Total revenues were RMB1,692.5 million (US$265.6 million), an increase of 30.7% from RMB1,295.0 million in fiscal year 2020.

 

·Information services and other revenues were RMB1,304.5 million (US$204.7 million), an increase of 35.6% from RMB962.1 million in fiscal year 2020. The increase was primarily attributable to an increase in average revenue per medical service provider.

 

·Reservation services revenues were RMB276.1 million (US$43.3 million), a decrease of 17.1% from RMB332.9 million in fiscal year 2020. The decrease was primarily due to the weaker-than-normal consumer sentiment and containment measures as a result of the resurgence of COVID-19, which had a negative impact on our operations in several cities across the country.

 

·Sales of equipment and maintenance services revenues were RMB112.0 million (US$17.6 million), from Wuhan Miracle, our newly acquired subsidiary.

 

3

 

 

Cost of Revenues

 

Cost of revenues were RMB327.9 million (US$51.5 million), an increase of 54.5% from RMB212.2 million in fiscal year 2020. The increase was primarily due to the consolidation of Wuhan Miracle. In addition, cost of revenues for fiscal year 2021 included share-based compensation expenses of RMB18.8 million (US$2.9 million) compared to RMB18.3 million in fiscal year 2020.

 

Operating Expenses

 

Total operating expenses were RMB1,397.1 million (US$219.2 million), an increase of 22.6% from RMB1,139.5 million in fiscal year 2020.

 

·Sales and marketing expenses were RMB792.5 million (US$124.4 million), an increase of 9.1% from RMB726.3 million in fiscal year 2020. The increase was primarily due to an increase in expenses associated with marketing campaigns and user acquisition initiatives and the consolidation of Wuhan Miracle. Sales and marketing expenses for fiscal year 2021 included share-based compensation expenses of RMB9.8 million (US$1.5 million), compared to RMB6.7 million in fiscal year 2020.

 

·General and administrative expenses were RMB252.2 million (US$39.6 million), an increase of 37.1% from RMB184.0 million in fiscal year 2020. This was primarily due to an increase in personnel related expenses and the consolidation of Wuhan Miracle. General and administrative expenses for 2021 included share-based compensation expenses of RMB56.7 million (US$8.9 million), compared to RMB46.0 million in fiscal year 2020.

 

·Research and development expenses were RMB286.6 million (US$45.0 million), an increase of 25.0% from RMB229.2 million in fiscal year 2020. The increase was primarily attributable to an increase in personnel related expenses. Research and development expenses for 2021 included share-based compensation expenses of RMB20.9 million (US$3.3 million), compared to RMB21.1 million in fiscal year 2020.

 

·Impairment of goodwill and intangible assets was RMB65.9 million (US$10.3 million), representing the amount by which the carrying amount of certain asset exceeds their fair value in relation to the acquiring subsidiary, based on an annual goodwill and intangible assets impairment assessment. The impairment of goodwill was RMB48.5 million (US$7.6 million) and the impairment of intangible assets was RMB17.4 million (US$2.7 million).

 

Income Tax (Expenses)/Benefit

 

Income tax expenses were RMB21.2 million (US$3.3 million), compared with an income tax benefit of RMB4.8 million in fiscal year 2020. The income tax benefit was derived from a change in the preferential income tax rate of one of So-Young’s subsidiaries, which resulted in a refund of RMB16.4 million for tax paid in previous periods.

 

Net income/(loss) attributable to So-Young International Inc.

 

Net loss attributable to So-Young International Inc. was RMB8.4 million (US$1.3 million), compared with a net income attributable to So-Young International Inc. of RMB5.8 million in fiscal year 2020.

 

Non-GAAP net income attributable to So-Young International Inc.

 

Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses and impairment of goodwill and intangible assets attributable to So-Young International Inc., was RMB139.5 million (US$21.9 million), compared with RMB98.0 million non-GAAP net income attributable to So-Young International Inc. in fiscal year 2020.

 

4

 

 

Basic and Diluted Earnings per ADS

 

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.08 (US$0.01) and RMB0.08 (US$0.01), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.05 and RMB0.05 in fiscal year 2020.

 

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

 

As of December 31, 2021, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,756.0 million (US$275.6 million), compared with RMB2,676.0 million as of December 31, 2020.

 

Business Outlook

 

For the first quarter of 2022, So-Young expects its total revenues to be between RMB290 million (US$46.0 million) and RMB300 million (US$47.0 million), representing a 19.4% to 16.6% decrease from the same period in 2021. The above outlook is based on the current market conditions and reflects the Company’s preliminary estimates of market and operating conditions, and customer demand, particularly in view of the potential impact of the COVID-19, the effects of which are difficult to analyze and predict, which are all subject to changes.

 

Non-GAAP Financial Measures

 

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP (loss)/income from operations and non-GAAP net (loss)/income attributable to So-Young International Inc. by excluding share-based compensation expenses and impairment of goodwill and intangible assets from (loss)/income from operations and net (loss)/income attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company’s operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company’s core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. The impairment of goodwill and intangible assets are considered unusual charges as the company does not have frequent such charges. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company’s results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses and impairment of goodwill and intangible assets in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company’s performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

 

About So-Young International Inc.

 

So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young’s strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.

 

5

 

 

Safe Harbor Statement

 

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young’s strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young’s strategies; So-Young’s future business development, financial condition and results of operations; So-Young’s ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young’s revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; the impact of the COVID-19 pandemic to So-Young’s business operations and the economy in China and elsewhere generally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

 

For more information, please contact:

 

So-Young

 

Investor Relations

Ms. Vivian Xu

Phone: +86-10-8790-2012

E-mail: ir@soyoung.com

 

Christensen

 

In China

Mr. Eric Yuan

Phone: +86-10-5900-1548

E-mail: Eyuan@christensenir.com

 

In US

Ms. Linda Bergkamp

Phone: +1-480-614-3004

Email: lbergkamp@christensenir.com

 

6

 

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except for share and per share data)

 

   As of 
  

December 31,

2020

  

December 31,

2021

  

December 31,

2021

 
   RMB   RMB   US$ 
Assets            
Current assets:               
Cash and cash equivalents   1,127,055    1,331,968    209,015 
Restricted cash and term deposits   21,865    15,119    2,373 
Trade receivables   52,871    54,829    8,604 
Inventories, net   -    91,812    14,407 
Receivables from online payment platforms   16,182    18,864    2,960 
Amounts due from related parties   7,764    14,038    2,203 
Term deposits and short-term investments   1,527,088    408,946    64,173 
Prepayment and other current assets   43,190    91,842    14,412 
Total current assets   2,796,015    2,027,418    318,147 
Non-current assets:               
Long-term investments   166,100    252,500    39,623 
Intangible assets   60,029    193,955    30,436 
Goodwill   48,500    540,693    84,847 
Property and equipment, net   29,830    124,576    19,549 
Deferred tax assets   55,520    47,520    7,457 
Operating lease right-of-use assets   120,140    95,609    15,003 
Other non-current assets   15,878    48,097    7,547 
Total non-current assets   495,997    1,302,950    204,462 
Total assets   3,292,012    3,330,368    522,609 
                
Liabilities               
Current liabilities:               
Taxes payable   60,070    48,571    7,622 
Contract liabilities   135,385    139,155    21,836 
Salary and welfare payables   95,758    103,624    16,261 
Amounts due to related parties   2,404    681    107 
Accrued expenses and other current liabilities   237,785    376,841    59,136 
Operating lease liabilities-current   39,468    43,529    6,831 
Total current liabilities   570,870    712,401    111,793 
Non-current liabilities:               
Operating lease liabilities-non current   93,044    62,356    9,785 
Deferred tax liabilities   8,522    38,577    6,054 
Total non-current liabilities   101,566    100,933    15,839 
Total liabilities   672,436    813,334    127,632 
                
Mezzanine equity               
Redeemable non-controlling interests   23,205    -    - 
Total mezzanine equity   23,205    -    - 

 

7

 

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Continued)

(All amounts in thousands, except for share and per share data, unless otherwise noted)

 

Shareholders’ equity:            
Treasury stock   -    (217,712)   (34,164)
Class A Ordinary shares (US$ 0.0005 par value; 750,000,000 shares authorized as of December 31, 2020 and December 31, 2021; 70,212,159 shares issued and outstanding as of December 31, 2020; 71,736,059 and 69,092,367 shares issued and outstanding as of December 31, 2021, respectively)   224    230    36 
Class B Ordinary shares (US$ 0.0005 par value; 20,000,000 shares authorized as of December 31, 2020 and December 31, 2021; 12,000,000 shares issued and outstanding as of December 31, 2020 and December 31, 2021)   37    37    6 
Additional paid-in capital   2,892,268    2,999,562    470,697 
Statutory reserves   10,562    20,331    3,190 
Accumulated deficit   (254,228)   (272,368)   (42,740)
Accumulated other comprehensive loss   (52,492)   (83,891)   (13,164)
Total So-Young International Inc. shareholders’ equity   2,596,371    2,446,189    383,861 
                
Non-controlling interests   -    70,845    11,116 
                
Total shareholders’ equity   2,596,371    2,517,034    394,977 
                
Total liabilities, mezzanine equity and shareholders’ equity   3,292,012    3,330,368    522,609 

 

8

 

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except for share and per share data)

  

   For the Three Months Ended   For the Fiscal Year Ended 
   December
31, 2020
   December
31, 2021
   December
31, 2021
   December
31, 2020
   December
31, 2021
   December
31, 2021
 
   RMB   RMB   US$   RMB   RMB   US$ 
Revenues                        
Information services and others   335,911    344,315    54,030    962,089    1,304,455    204,697 
Reservation services   88,724    41,372    6,493    332,899    276,052    43,320 
Sales of equipment and maintenance services   -    63,836    10,017    -    111,956    17,568 
Total revenues   424,635    449,523    70,540    1,294,988    1,692,463    265,585 
Cost of revenues   (63,620)   (127,090)   (19,943)   (212,206)   (327,889)   (51,453)
Gross profit   361,015    322,433    50,597    1,082,782    1,364,574    214,132 
Operating expenses:                              
Sales and marketing expenses   (210,378)   (152,656)   (23,955)   (726,297)   (792,484)   (124,358)
General and administrative expenses   (49,888)   (85,852)   (13,472)   (183,987)   (252,214)   (39,578)
Research and development expenses   (70,920)   (67,519)   (10,595)   (229,192)   (286,567)   (44,969)
Impairment of goodwill and intangible assets   -    (65,879)   (10,338)   -    (65,879)   (10,338)
Total operating expenses   (331,186)   (371,906)   (58,360)   (1,139,476)   (1,397,144)   (219,243)
Income/(loss) from operations   29,829    (49,473)   (7,763)   (56,694)   (32,570)   (5,111)
Other income/(expenses):                              
Investment income   3,130    927    145    13,599    8,931    1,401 
Interest income   6,753    3,654    573    39,669    19,328    3,033 
Exchange (losses)/gain   (603)   33    5    (1,118)   (4,766)   (748)
Impairment of long-term investment   -    -    -    -    (17,850)   (2,801)
Share of gain/(losses) of equity method investee   198    (746)   (117)   (4,279)   (1,522)   (239)
Others, net   11,407    2,208    346    8,916    12,044    1,890 
Income/(loss) before tax   50,714    (43,397)   (6,811)   93    (16,405)   (2,575)
Income tax (expenses)/benefit   (12,997)   (10,145)   (1,592)   4,784    (21,231)   (3,332)
Net income/(loss)   37,717    (53,542)   (8,403)   4,877    (37,636)   (5,907)
Net loss attributable to noncontrolling interests   930    25,806    4,050    930    29,265    4,592 
Net income/(loss) attributable to So-Young International Inc.   38,647    (27,736)   (4,353)   5,807    (8,371)   (1,315)

 

9 

 

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Continued)

(Amounts in thousands, except for share and per share data)

 

   For the Three Months Ended   For the Fiscal Year Ended 
   December
31, 2020
   December
31, 2021
   December
31, 2021
   December
31, 2020
   December
31, 2021
   December
31, 2021
 
   RMB   RMB   US$   RMB   RMB   US$ 
Net income/(loss) per ordinary share                              
Net earnings/(loss) per ordinary share attributable to ordinary shareholder - basic   0.47    (0.34)   (0.05)   0.07    (0.10)   (0.02)
Net earnings/(loss) per ordinary share attributable to ordinary shareholder - diluted   0.46    (0.34)   (0.05)   0.07    (0.10)   (0.02)
Net earnings/(loss) per ADS attributable to ordinary shareholders - basic (13 ADS represents 10 Class A ordinary shares)   0.36    (0.26)   (0.04)   0.05    (0.08)   (0.01)
Net earnings/(loss) per ADS attributable to ordinary shareholders - diluted (13 ADS represents 10 Class A ordinary shares)   0.35    (0.26)   (0.04)   0.05    (0.08)   (0.01)
Weighted average number of ordinary shares used in computing earnings/(loss) per share, basic*   81,904,047    81,304,182    81,304,182    81,534,991    81,680,504    81,680,504 
Weighted average number of ordinary shares used in computing earnings/(loss) per share, diluted*   84,108,250    81,304,182    81,304,182    83,781,406    81,680,504    81,680,504 
                               
Share-based compensation expenses included in:                              
Cost of revenues   (5,040)   (5,830)   (915)   (18,327)   (18,768)   (2,945)
Sales and marketing expenses   (2,183)   (3,719)   (584)   (6,711)   (9,808)   (1,539)
General and administrative expenses   (11,311)   (32,259)   (5,062)   (46,001)   (56,705)   (8,898)
Research and development expenses   (5,943)   (7,106)   (1,115)   (21,131)   (20,869)   (3,275)
*Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.

 

10 

 

 

SO-YOUNG INTERNATIONAL INC.

Reconciliation of GAAP and Non-GAAP Results

(Amounts in thousands, except for share and per share data)

 

   For the Three Months Ended   For the Fiscal Year Ended 
   December
31, 2020
   December
31, 2021
   December
31, 2021
   December
31, 2020
   December
31, 2021
   December
31, 2021
 
   RMB   RMB   US$   RMB   RMB   US$ 
GAAP income/(loss) from operations   29,829    (49,473)   (7,763)   (56,694)   (32,570)   (5,111)
Add back: Shared-based compensation expenses   24,477    48,914    7,676    92,170    106,150    16,657 
Add back: Impairment of goodwill and intangible assets   -    65,879    10,338    -    65,879    10,338 
Non-GAAP income from operations   54,306    65,320    10,251    35,476    139,459    21,884 
                               
                               
GAAP Net income/(loss) attributable to So-Young International Inc.   38,647    (27,736)   (4,353)   5,807    (8,371)   (1,315)
Add back: Shared-based compensation expenses   24,477    48,914    7,676    92,170    106,150    16,657 
Add back: Impairment of goodwill and intangible assets attributable to So-Young International Inc.   -    41,748    6,551    -    41,748    6,551 
Non-GAAP Net income attributable to So-Young International Inc.   63,124    62,926    9,874    97,977    139,527    21,893 

  

11